An interventional study of SCThrive and SCHealthED in Anemia, Sickle Cell, sponsored by Children's Hospital Medical Center, Cincinnati. Recruiting at 4 sites in United States. Open to participants aged 13 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 11 under way, none of them phase 3. Anemia, Sickle Cell · Children's Hospital Medical Center, Cincinnati.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, this one is the 3rd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 with no phase, reaches primary completion later than 6 of the 10 other live ones, and was the 24th registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →7 of the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati are open now, in 6 countries. Recruiting first, the newest first:
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Children's Hospital Medical Center, Cincinnati · Sites in United States, Ghana, Tanzania
Ages 6 mo–6 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 6 mo+
Children's Hospital Medical Center, Cincinnati · Sites in Dominican Republic, Jamaica, Tanzania
Ages 8+
Children's Hospital Medical Center, Cincinnati · Sites in United States
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 13 Years to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 310 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 66 across the 21 interventional studies, 200 across the 9 observational. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
4 of the studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07177300Children's Hospital Medical Center, CincinnatiEffectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE) | 2026-12 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Anemia, Sickle Cell by Children's Hospital Medical Center, Cincinnati, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the impact of SCThrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency room visits in 260 adolescents and young adults with sickle cell disease (SCD) ages 13-21 receiving care at 1 of 4 pediatric SCD clinics.
The main question[s]it aims to answer are:
Participants will complete self-management related surveys before, after, and 3 months following their participation in an 8- week, virtual group intervention with an accompanying mobile app (SCThrive).
Researchers will compare outcomes for participants who receive SCThrive and participants who receive uniform standard care (SCHealthED which = standard of care plus SCD educational text messages) to see if there are differences in patient activation, self-management behaviors, daily functioning, and emergency room visits.
The research team's pilot work demonstrated improved patient activation (knowledge, skills, and self-efficacy) and self-management behaviors in adolescents and young adults (AYA) with sickle cell disease (SCD) compared to a control condition. Further analyses revealed that participants who used the app more frequently showed greater improvements. Thus, this study will maximize the clinical benefit of SCThrive by 1) adding app engagement strategies, 2) conducting a more systematic assessment of barriers including social contributors to health, and 3) integrating ways to address these barriers into the intervention.
Study Aims: The aims are to examine the impact of SCThrive on patient activation (primary outcome; Aim 1) and self-management behaviors, daily functioning, and emergency room visits (secondary outcomes) at post-treatment and follow-up (Aim 2). It is hypothesized that adolescents randomized to SCThrive will have greater improvement in patient activation (primary outcome) compared to those randomized to uniform standard care (control condition). The research team will also explore the relationship between social determinants of health (SDOH)-related barriers (e.g., stigma, access to care) and treatment response (i.e., patient activation and self-management behaviors).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
Behavioral: SCThrive
Participants randomized to SCHealthED will receive usual care plus 7 text messages consisting of SCD educational facts to ensure the care is uniform across sites.
Other: SCHealthED
SCThrive is a virtual, 8-week, virtual group-based, behavioral self-management intervention that includes daily use of a companion mobile app.
Standard of care plus 7 SCD educational text messages to ensure education is uniform across sites
Also known as: Uniform Standard Care
Patient Activation
Self-reported patient activation as measured by the Patient Activation Measure -13 (PAM-13), which is a 13 item measure on skills, knowledge, confidence and readiness for self-management developed by Hibbard et al., 2005. Items are rated on a 4-point Likert scale of 1 = "Disagree Strongly" to 3 = "Strongly Agree." Raw scores range from 13 to 52 and are converted to scores that range from 0 to 100. This score was then divided into four levels of activation, which reflect a developmental progression from being passive with regard to one's health to being proactive: Level 1 (score of 0.0 - 47.0), Level 2 (47.1 - 55.1), Level 3 (55.2 - 72.4), and Level 4 (72.5 - 100). Higher scores indicate more behavioral activation.
Time frame: baseline, up to 4 weeks after treatment ends, 3 to 4 months after treatment ends
Self-Management Behaviors
self-reported self-management behaviors as measured by the Transition Readiness Assessment Questionnaire - 6 (TRAQ-6), which is a well-validated 20-item questionnaire that measures the skills needed to manage a chronic condition independently. Items are rated on a 5-point Likert scale of 1 = "No, I do not know how" to 5 = "Yes, I always do this when I need to" and divided into 5 subscales: Managing Medication, Appointment Keeping, Tracking Health Issues, Talking with Providers, and Managing Daily Activities. Overall and subscale scores are calculated by averaging the scores of answered items. Mean scores range from 1 to 5 with higher scores indicating better self-management.
Time frame: baseline, up to 4 weeks after treatment ends, 3 to 4 months after treatment ends
Daily Functioning
The Functional Disability Inventory is a self-report measure of limitations in children's physical and psychosocial functioning due to their physical health. The instrument consists of 15 items concerning activity limitations due to "being sick or not feeling well" during the past 2 weeks. Total scores ranging from 0 to 60 are computed by summing the ratings for each of the 15 items on the FDI. Higher scores indicate greater perceived functional disability.
Time frame: baseline, up to 4 weeks after treatment ends, 3 to 4 months after treatment ends
Emergency Room (ER) Visits
number of emergency room visits
Time frame: 6 months prior to treatment; 6 months post-treatment
Self-Management Skills
Participants complete the UNC TRxANSITION Scale, an interview administered by trained independent evaluators to measure the skills of youth with chronic conditions. For this study, we will administer 6 of the 10 possible subscales: Type of Chronic Health Condition, Medications, Adherence, Nutrition, Self-Management Skills, and New Health Care Providers. Each item is scored individually as either 1 (adequate knowledge/skill mastery), 0.5 (some knowledge/skill attainment), or 0 (no knowledge/skill attainment). Higher scores indicate better self-management. Subscale scores are calculated by dividing the patient's score by the total possible subscale score. Subscale scores are then combined to create a total score, ranging from 0 to 10, but since we will only use 6 scales, 0 to 6. Total and subscale proportion scores will be used in analyses.
Time frame: baseline, up to 4 weeks after treatment ends, 3 to 4 months after treatment ends
Health-related quality of life
Patient report of sickle cell disease (SCD)-specific quality of life (QOL) and pain, as measured by the Pediatric Quality of Life (PedsQL) SCD Module, which assesses several domains of health-related quality of life (HRQOL), including pain impact, fatigue, pain management, emotions, communication, and treatment adherence. Total score only. Scores range from 0 to 100, with higher scores indicating higher HRQOL or higher functioning.
Time frame: baseline, up to 4 weeks after treatment ends, 3 to 4 months after treatment ends
Plan to share: No — Only de-identified data will be shared with other researchers. Deidentified data sets will be available on the Open Science Framework.
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jan 2028, 35 months after the start.
Of 165 non-industry interventional studies with no phase under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 35 months is above that.
Counting every sponsor, half of 173 studies reached it within 28 months; a quarter within 15 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital Medical Center, Cincinnati →